Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.71 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.71 |
| ▸ | P4HB | P07237 | 5/20 | 0.71 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.71 |
| ▸ | MAOA | P21397 | 4/20 | 0.71 |
| ▸ | XDH | P47989 | 4/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.71 |
| ▸ | SLCO2B1 | O94956 | 3/20 | 0.71 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | CA12 | O43570 | 2/20 | 0.71 |
| ▸ | CA2 | P00918 | 2/20 | 0.71 |
| ▸ | CA4 | P22748 | 2/20 | 0.71 |
| ▸ | CA7 | P43166 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 7/20 | 0.69 |
| ▸ | POLB | P06746 | 6/20 | 0.69 |
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | ALPI | P09923 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Reynoutrin SCHEMBL31130799 | 1.00 | KDM4E (0.71) | KDM4EAKR1B1P4HBEPHX2MAOA | |
| Reynoutrin SCHEMBL14350762 | 1.00 | KDM4E (0.71) | KDM4EAKR1B1P4HBEPHX2MAOA | |
| Reynoutrin SCHEMBL3641504 | 1.00 | KDM4E (0.71) | KDM4EAKR1B1P4HBEPHX2MAOA | |
| Reynoutrin SCHEMBL4226891 | 1.00 | KDM4E (0.71) | KDM4EAKR1B1P4HBEPHX2MAOA | |
| Reynoutrin SCHEMBL5590747 | 1.00 | KDM4E (0.71) | KDM4EAKR1B1P4HBEPHX2MAOA | |
| Reynoutrin SCHEMBL20298285 | 1.00 | KDM4E (0.71) | KDM4EAKR1B1P4HBEPHX2MAOA | |
| Guajaverin SCHEMBL3635416 | 1.00 | KDM4E (0.71) | KDM4EAKR1B1P4HBEPHX2MAOA | |
| Reynoutrin SCHEMBL6759025 | 1.00 | KDM4E (0.71) | KDM4EAKR1B1P4HBEPHX2MAOA | |
| Reynoutrin SCHEMBL6119167 | 1.00 | KDM4E (0.71) | KDM4EAKR1B1P4HBEPHX2MAOA | |
| Reynoutrin SCHEMBL28550462 | 1.00 | KDM4E (0.71) | KDM4EAKR1B1P4HBEPHX2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | claimed |
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | disclosed |
| EP-3780974-A1 | GUAVA EXTRACT | PM-International AG (LU) | 2021-02-24 | — | — | EP | disclosed |
| US-20200297692-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | MERCK SHARP & DOHME CORP. (US) | 2020-09-24 | — | — | US | disclosed |
| US-10709684-B2 | SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | MERCK SHARP & DOHME CORP. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20200054598-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | MERCK SHARP & DOHME CORP. (US) | 2020-02-20 | — | — | US | disclosed |
| US-10500186-B2 | SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | MERCK SHARP & DOHME CORP. (US) | 2019-12-10 | — | — | US | disclosed |
| WO-2019201425-A1 | GUAVA EXTRACT | PM-INTERNATIONAL AG (LU) | 2019-10-24 | — | — | WO | disclosed |
| US-20190142793-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
| US-10285973-B2 | SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | MERCK SHARP & DOHME CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| WO-2010023594-A1 | DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100056618-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC | 2010-03-04 | — | — | US | disclosed |
| US-20070292539-A1 | Anti-inflammatory cranberry flavonol extract preparations | VORSA NICHOLI | 2007-12-20 | — | — | US | disclosed |
| US-20070292539-A1 | Anti-inflammatory cranberry flavonol extract preparations | VORSA NICHOLI | 2007-12-20 | — | — | US | disclosed |
| US-20070292539-A1 | Anti-inflammatory cranberry flavonol extract preparations | VORSA NICHOLI | 2007-12-20 | — | — | US | disclosed |
| US-7270837-B2 | free of anthocyanins and proanthocyanidins; treatment of inflammatory disorders, particularly irritation of the urinary tract due to both bacterial and non-bacterial causes | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2007-09-18 | — | — | US | disclosed |
| US-7270837-B2 | free of anthocyanins and proanthocyanidins; treatment of inflammatory disorders, particularly irritation of the urinary tract due to both bacterial and non-bacterial causes | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2007-09-18 | — | — | US | disclosed |
| US-7270837-B2 | free of anthocyanins and proanthocyanidins; treatment of inflammatory disorders, particularly irritation of the urinary tract due to both bacterial and non-bacterial causes | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2007-09-18 | — | — | US | disclosed |
| US-20060088610-A1 | Anti-inflammatory cranberry flavonol extract preparations | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2006-04-27 | — | — | US | disclosed |
| US-20060088610-A1 | Anti-inflammatory cranberry flavonol extract preparations | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056618-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | KDM4E 3890/4885AKR1B1 195/4885P4HB 2590/4885 |
| US-10285973-B2 | SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | SLC5A1, SLC5A2, SLC2A1 | KDM4E 1229/4885AKR1B1 946/4885P4HB 4129/4885 |
| US-10500186-B2 | SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | SLC5A1, SLC5A2, SLC2A1 | KDM4E 1229/4885AKR1B1 946/4885P4HB 4129/4885 |
| US-20200297692-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | SLC5A1, SLC5A2, SLC2A1 | KDM4E 1229/4885AKR1B1 946/4885P4HB 4129/4885 |
| US-20070292539-A1 | Anti-inflammatory cranberry flavonol extract preparations | LGALS3, FUT6, GALNT6 | KDM4E 714/4885AKR1B1 2465/4885P4HB 4447/4885 |
| US-20200054598-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | SLC5A1, SLC5A2, SLC2A1 | KDM4E 1229/4885AKR1B1 946/4885P4HB 4129/4885 |
| US-20060088610-A1 | Anti-inflammatory cranberry flavonol extract preparations | LGALS3, FUT6, GALNT6 | KDM4E 714/4885AKR1B1 2465/4885P4HB 4447/4885 |
| US-10709684-B2 | SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease | SLC5A1, SLC5A2, SLC2A1 | KDM4E 1229/4885AKR1B1 946/4885P4HB 4129/4885 |
| US-20190142793-A1 | SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE | SLC5A1, SLC5A2, SLC2A1 | KDM4E 1227/4885AKR1B1 923/4885P4HB 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.